<code id='D84656445B'></code><style id='D84656445B'></style>
    • <acronym id='D84656445B'></acronym>
      <center id='D84656445B'><center id='D84656445B'><tfoot id='D84656445B'></tfoot></center><abbr id='D84656445B'><dir id='D84656445B'><tfoot id='D84656445B'></tfoot><noframes id='D84656445B'>

    • <optgroup id='D84656445B'><strike id='D84656445B'><sup id='D84656445B'></sup></strike><code id='D84656445B'></code></optgroup>
        1. <b id='D84656445B'><label id='D84656445B'><select id='D84656445B'><dt id='D84656445B'><span id='D84656445B'></span></dt></select></label></b><u id='D84656445B'></u>
          <i id='D84656445B'><strike id='D84656445B'><tt id='D84656445B'><pre id='D84656445B'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:36689

          When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

          advertisement

          For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Medicare drug price negotiation hasn't dried up venture capital
          Medicare drug price negotiation hasn't dried up venture capital

          AdobeWASHINGTON—VenturecapitalistsarestillpouringmoneyintodrugresearchinspiteofMedicare’snewpowerton

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          SNAP should offer more nutrition education

          StaffandvolunteersattheHungryMonkfoodpantryprepareanddistributefruitandvegetablestolocalresidentsatt